CAS: 23100-12-1; 6-Chloronicotinaldehyde

相似化合物

33252-28-7 49608-01-7 5326-23-8

上下游产品

6-chloronicotinonitrile 1-(6-chloronicotinyl)-2-nitroiminoimidazoline 6-chloro-3-vinyl-pyridine ethyl (E)-3-(6-chloropyridin-3-yl)acrylate 4-[1-(6-Chloro-pyridin-3-yl)-meth-(Z)-ylidene]-2-phenyl-4H-oxazol-5-one 3-amino-3-(6-chloro-pyridin-3-yl)-propionic acid

6-溴烟酸置于sodium Tetrahydroborate,二甲基亚砜,三氟乙酸,三氯氧磷体系中,用 二氯甲烷 用作溶剂,化学反应 4.5H,反应生成6-氯烟醛
参考文献:Substituted Dipyridylethenes And-Ethynes And Key Pyridine Building Blocks
标题:Substituted Dipyridylethenes And-Ethynes And Key Pyridine Building Blocks
摘要:合成了多种新的2,5-二取代吡啶.通过还原烟酸3,氨基二甲基吡啶6的水解或5-溴吡啶12和14与丁基锂在dmf中的反应,得到了2-取代的5-醛基吡啶8,15A-B.双吡啶乙烯16A-B,E通过wadsworth-Emmons反应与吡啶基膦酸酯7合成,或者通过mcmurry反应将醛偶联形成烯烃16C-D.在双吡啶乙烯16A-D的c=c双键溴化后,经过1,2-双吡啶-1,2-二溴乙烷17A-D的消除,得到了双吡啶乙炔18A-D.
Doi:10.1055/s-1994-25411

专利信息

专利号:US-10538490-B2
优先权日:2016-10-25
标题:Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
发明人：ECKHARDT MATTHIAS; PETERS STEFAN; WAGNER HOLGER
权利人:BOEHRINGER INGELHEIM INT
摘要:The present invention relates to compounds of general formula I, n nwherein the groups R, R 1 , R 2 , R 3 , m and n are defined herein, which have valuable pharmacological properties, including binding to the GPR40 receptor and modulating its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

专利号:US-2010249192-A1
优先权日:2007-12-11
标 题 :Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
发明人：LI CHUN SING; RAMTOHUL YEEMAN K; LECLERC JEAN-PHILIPPE
权利人:MERCK FROSST CANADA LTD
摘要:Heteroaromatic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; Metabolic Syndrome; insulin resistance; cancer; liver steatosis; and non-alcoholic steatohepatitis. n HetAr − W − X − Ar  (I)

专利号:US-5654439-A
优先权日:1994-01-11
标 题:N-1-alkyl-2,5-Di(trialkyl silyl) pyrrolidines
发明人：PANDEY GANESH; BAGUL TRUSAR DAMU; LAKSHMAIAH GINGIPALLI
权利人:COUNCIL SCIENT IND RES
摘要:A novel 6-chloro-3-vinyl-pyridine of formula ##STR1## where X represents --H, --SO 2 Ph, --CO 2 Et, --COCH 3 and --CHO; which is used for the synthesis of Epibatidine of formula ##STR2## by reacting said 6-chloro-3-vinyl pyridine with N-1-alkyl-2,5-di(trialkyl silyl) pyrrolidine of formula ##STR3## to obtain N-alkyl Epibatidine which is hydrogenated to obtain the Epibatidine.

专利号:US-9617251-B2
优先权日:2015-08-07
标题:Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
发明人：ECKHARDT MATTHIAS; PETERS STEFAN; WAGNER HOLGER
权利人:BOEHRINGER INGELHEIM INT
摘要:The present invention relates to compounds of general formula I, n nwherein the groups R, R 1 , R 2 , R 3 , m and n are defined as in claim 1 , which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

专利号:US-6844441-B2
优先权日:2000-03-31
标 题:Process for preparing substituted pyridines
发明人：DOW ROBERT L; SCHNEIDER STEVEN R
权利人:PFIZER
摘要:A process for preparing a compound of the formula: n n nwherein n, R 1 , R 2 , R 3 and X are as defined above, used as an intermediate in the synthesis of β-adrenergic receptor agonists.

专利号:US-2009137577-A1
优先权日:2007-06-29
标 题 :Heterocyclic compounds
发明人：DUPLANTIER ALLEN J; EFREMOV IVAN; ZHANG LEI; MAKLAD NOHA S; O'SULLIVAN THERESA
权利人:PFIZER
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n n n n n n n n n n as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.